{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:34:13Z","timestamp":1792481653142,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejmech.2024.116590","type":"journal-article","created":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T21:56:59Z","timestamp":1718575019000},"page":"116590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation"],"prefix":"10.1016","volume":"275","author":[{"given":"Han","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longcai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-6200","authenticated-orcid":false,"given":"Xingshu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116590_bib1","doi-asserted-by":"crossref","first-page":"2445e2459","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116590_bib2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116590_bib3","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116590_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"# 5","key":"10.1016\/j.ejmech.2024.116590_bib5","article-title":"A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors","volume":"35","author":"Bierbrier","year":"2022","journal-title":"Dermatol. Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116590_bib6","article-title":"Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer","volume":"2017","author":"Chan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"# 12","key":"10.1016\/j.ejmech.2024.116590_bib7","doi-asserted-by":"crossref","first-page":"11701","DOI":"10.1007\/s13277-014-2660-z","article-title":"EGFR inhibitors and autophagy in cancer treatment","volume":"35","author":"Cui","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejmech.2024.116590_bib8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116590_bib9","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-06-0714","article-title":"Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib","volume":"12","author":"Kosaka","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116590_bib10","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-10-2571","article-title":"New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116590_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116590_bib12","doi-asserted-by":"crossref","first-page":"560e562","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116590_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116590_bib14","doi-asserted-by":"crossref","first-page":"3913e3923","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors","volume":"21","author":"Ercan","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116590_bib15","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116590_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116590_bib17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1021\/acsmedchemlett.8b00564","article-title":"Discovery of potent and Noncovalent Reversible EGFR kinase inhibitors of EGFRL858R\/T790M\/C797S","volume":"10","author":"Li","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"# 7","key":"10.1016\/j.ejmech.2024.116590_bib18","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.ejmech.2024.116590_bib19","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.1021\/acs.jmedchem.1c01055","article-title":"Potent and selective inhibitors of the epidermal growth factor receptor to overcome C797S-mediated resistance","volume":"64","author":"Finlay","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116590_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes Osimertinib resistance in EGFR-mutated non small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116590_bib21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1535-7163.MCT-21-0835","article-title":"HJM-561, a potent, selective, and orally Bioavailable EGFR PROTAC that overcomes Osimertinib-resistant EGFR triple mutations","volume":"21","author":"Du","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116590_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cas.15229","article-title":"LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo","volume":"113","author":"Liu","year":"2022","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116590_bib23","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1021\/acs.jmedchem.3c00277","article-title":"Discovery of potent and Wild-Type-Sparing Fourth-generation EGFR inhibitors for treatment of Osimertinib-resistance NSCLC","volume":"66","author":"Dong","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116590_bib24","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a Reversible, potent, and WildType-Sparing Next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116590_bib25","unstructured":"Lee, K.; Shin, I.; Choi, G.; Chae, C. H.; Choe, H. J.; Jung, M. E.; Jeon, B. U.; Cho, B. C.; Park, C. W.; Kim, H.; et al. WO2018230934 A1."},{"issue":"22","key":"10.1016\/j.ejmech.2024.116590_bib26","doi-asserted-by":"crossref","first-page":"10272","DOI":"10.1021\/acs.jmedchem.9b01169","article-title":"Start selective and Rigidify: the discovery Path toward a Next generation of EGFR tyrosine kinase inhibitors","volume":"62","author":"Engelhardt","year":"2019","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116590_bib27","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes Osimertinib-resistant EGFR-Del19\/T790M\/C797S mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"issue":"15","key":"10.1016\/j.ejmech.2024.116590_bib28","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.1021\/acs.jmedchem.9b00576","article-title":"Structure-based design of 5-Methylpyrimidopyridone derivatives as new Wild-Type Sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFRL858R\/T790M\/C797S)","volume":"62","author":"Shen","year":"2019","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116590_bib29","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1021\/acs.jmedchem.2c00168","article-title":"Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine derivatives as new Fourth-generation epidermal growth factor receptor inhibitors targeting T790M\/C797S mutations","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116590_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114856","article-title":"Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors","volume":"244","author":"Dou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2024.116590_bib31","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1021\/acs.jmedchem.1c00373","article-title":"Discovery of a Brigatinib Degrader SIAIS164018 with Destroying metastasis-related Oncoproteins and a Reshuffling Kinome Profile","volume":"64","author":"Ren","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116590_bib32","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1021\/acsmedchemlett.9b00381","article-title":"Discovery and optimization of Dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors","volume":"10","author":"De Clercq","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"19","key":"10.1016\/j.ejmech.2024.116590_bib33","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1021\/acs.jmedchem.6b00472","article-title":"The \u201ccyclopropyl fragment\u201d is a Versatile player that Frequently Appears in Preclinical\/clinical drug molecules","volume":"59","author":"Tanaji","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116590_bib34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejmech.2018.09.012","article-title":"Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives","volume":"158","author":"Guo","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116590_bib35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/acsmedchemlett.1c00555","article-title":"Optimization of Brigatinib as new Wild-Type Sparing inhibitors of EGFRT790M\/C797S mutants","volume":"13","author":"Li","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116590_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci400539q","article-title":"Halogen bond: its role beyond drug-target binding affinity for drug discovery and development","volume":"54","author":"Xu","year":"2014","journal-title":"J. Chem. Inf. Model."},{"issue":"20","key":"10.1016\/j.ejmech.2024.116590_bib37","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1016\/j.bmcl.2018.09.016","article-title":"Methyl-containing pharmaceuticals: methylation in drug design","volume":"28","author":"Sun","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"47","key":"10.1016\/j.ejmech.2024.116590_bib38","doi-asserted-by":"crossref","first-page":"12256","DOI":"10.1002\/anie.201303207","article-title":"Profound methyl effects in drug discovery and a call for new C-H methylation reactions","volume":"52","author":"Sch\u00f6nherr","year":"2013","journal-title":"Angew. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116590_bib39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/pros.23940","article-title":"The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells","volume":"80","author":"Gruber","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2024.116590_bib40","article-title":"Ultra-sensitive detection of tumorigenic cellular impurities in human cell-processed therapeutic products by digital analysis of soft agar colony formation","volume":"5","author":"Kusakawa","year":"2016","journal-title":"Sci. Rep."},{"issue":"5547","key":"10.1016\/j.ejmech.2024.116590_bib41","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1126\/science.1064829","article-title":"Taking cell-matrix adhesions to the third dimension","volume":"294","author":"Cukierman","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116590_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/bcr2800","article-title":"3D culture reveals a signaling network","volume":"13","author":"Muthuswamy","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116590_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jcp.24683","article-title":"3D cell culture Systems: advantages and Applications","volume":"230","author":"Ravi","year":"2015","journal-title":"J. Cell. Physiol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:25:50Z","timestamp":1720445150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424004707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":43,"alternative-id":["S0223523424004707"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116590","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116590"}}